GONAL- f behandling giver sjældent stigende signifikant OHSS med mindre at medicinen anvendes til at reducere follikel modning (indeholder humant chorion gonadotropin – hCG).
GONAL-f treatment seldom gives rise to significant OHSS unless the medicine used to induce final follicular maturation (containing human chorionic gonadotrophin - hCG) is administered.